Recombinant proteins A29L, M1R, A35R, and B6R vaccination protects mice from mpox virus challenge

• Published in: Frontiers in immunology 2023-06, Vol.14, p.1203410-1203410
• Main Authors: Tang, Ding, Liu, Xiaoke, Lu, Jia, Fan, Huifen, Xu, Xiuli, Sun, Kaili, Wang, Ruyu, Li, Chunyang, Dan, Demiao, Du, Hongqiao, Wang, Zejun, Li, Xinguo, Yang, Xiaoming
• Format: Article
• Language: English
• Subjects: Animals; antibody response; Immunology; Mice; Mice, Inbred BALB C; Monkeypox virus; Mpox (monkeypox) - prevention & control; mpox virus; recombinant protein; Recombinant Proteins; Smallpox Vaccine; Vaccination; virus challenge
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2023.1203410

Since May 2022, mutant strains of mpox (formerly monkeypox) virus (MPXV) have been rapidly spreading among individuals who have not traveled to endemic areas in multiple locations, including Europe and the United States. Both intracellular and extracellular forms of mpox virus have multiple outer membrane proteins that can stimulate immune response. Here, we investigated the immunogenicity of MPXV structural proteins such as A29L, M1R, A35R, and B6R as a combination vaccine, and the protective effect against the 2022 mpox mutant strain was also evaluated in BALB/c mice. After mixed 15 μg QS-21 adjuvant, all four virus structural proteins were administered subcutaneously to mice. Antibody titers in mouse sera rose sharply after the initial boost, along with an increased capacity of immune cells to produce IFN-γ alongside an elevated level of cellular immunity mediated by Th1 cells. The vaccine-induced neutralizing antibodies significantly inhibited the replication of MPXV in mice and reduced the pathological damage of organs. This study demonstrates the feasibility of a multiple recombinant vaccine for MPXV variant strains.